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Abstract
Background: The peroxisome proliferator activated receptor (PPAR) subgroup of the nuclear hormone receptor
superfamily is activated by a variety of natural and synthetic ligands. PPARs can heterodimerize with retinoid X
receptors, which have homology to other members of the nuclear receptor superfamily. Ligand binding to PPAR/
RXRs results in recruitment of transcriptional coactivator proteins such as steroid receptor coactivator 1 (SRC-1) and
CREB binding protein (CBP). Both SRC-1 and CBP are histone acetyltransferases, which by modifying nucleosomal
histones, produce more open chromatin structure and increase transcriptional activity. Nuclear hormone receptors
can recruit limiting amounts of coactivators from other transcription factor binding sites such as AP-1, thereby
inhibiting the activity of AP-1 target genes. PPAR and RXR ligands have been used in experimental breast cancer
therapy. The role of coactivator expression in mammary tumorigenesis and response to drug therapy has been the
subject of recent studies.
Methods: We examined the effects of loss of SRC-1 on MMTV-neu mediated mammary tumorigenesis.
Results: SRC-1 null mutation in mammary tumor prone mice increased the tumor latency period, reduced tumor
proliferation index and metastasis, inhibited response to PPAR and RXR ligands, and induced genes involved in
mammary gland differentiation. We also examined human breast cancer cell lines overexpressing SRC-1 or CBP.
Coactivator overexpression increased cellular proliferation with resistance to PPAR and RXR ligands and remodeled
chromatin of the proximal epidermal growth factor receptor promoter.
Conclusions: These results indicate that histone acetyltransferases play key roles in mammary tumorigenesis and
response to anti-proliferative therapies.
Background
The peroxisome proliferator activated receptor (PPAR)
subgroup of the nuclear hormone receptor superfamily
are activated by a variety of ligands such as fatty acids,
prostaglandin J2 metabolites, fibrates, and thiazolidine-
dione drugs [for review see [1,2]]. Clofibrate is approved
for treatment of hyperlipidemia while ciglitazone analogs
are used as antidiabetic drugs. Both classes of drugs
have been used as experimental cancer therapies. PPARs
have functional domains for DNA and ligand binding
and interact with recognition sequences in the promoter
regions of their target genes to regulate transcription
[3]. PPARs can heterodimerize with retinoid X recep-
tors, which have homology to other members of the
nuclear receptor superfamily [4]. Natural and synthetic
ligands for RXRs, such as, AGN194204 have been char-
acterized, and heterodimerization with PPARs greatly
enhances DNA binding and transcriptional activation
[5-7]. RXR selective ligands were highly effective in pre-
clinical models of mammary cancer.
Ligand binding to PPARs results in recruitment of
transcriptional coactivator proteins such as steroid
receptor coactivator 1 (SRC-1) and CREB binding
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transferases, which by modifying nucleosomal histones,
produce more open chromatin structure and increase
transcriptional activity [8,9]. Members of the SRC family
(SRC-1, -2, and -3) share ~40% sequence identity, a
basic helix-loop-helix domain involved in dimerization
and DNA interaction, and a PAS domain for protein
interaction. LXXLL motifs, which allow binding to
nuclear receptors, are located in the central region of
these proteins [10]. Nuclear hormone receptors can
recruit limiting amounts of coactivators from other tran-
scription factor binding sites such as AP-1, thereby inhi-
biting the activity of AP-1 target genes [11]. Expression
of the SRC family member SRC-3 is amplified or over-
expressed in breast and ovarian cancer [12,13]. Translo-
cation of the SRC-2 and monocytic zinc finger (MOZ)
gene has been demonstrated in acute myeloid leukemia
[14]. SRC-1 null mutant mice are viable and fertile but
exhibit partial resistance to many hormones including
estrogen, progestin, androgen, and thyroid [15,16]. We
previously demonstrated that SRC-1 expression
imparted estrogen responsiveness to non-reproductive
tract cancer cell lines [17].
PPAR and RXR ligands have been used in experimen-
tal cancer therapies [18]. Human breast cancer cells
express PPARs and RXRs, and ligands for these recep-
tors have been shown to induce growth inhibition and
apoptosis in cell cultures and animal models [19-24].
These PPAR and RXR ligands generally did not produce
dose limiting side effects, but clinical trials failed to
show objective responses in patients with advanced
breast cancer [25,26]. The role of coactivator expression
in this lack of response to drug therapy has recently
received attention. A previous study from our laboratory
demonstrated that coactivator overexpression produced
resistance to the nuclear hormone retinoic acid [27].
Similarly altered SRC-1 expression has been associated
with resistance to anti-estrogen therapy and CBP is
overexpressed in some breast cancers [28,29]. Previous
studies demonstrated decreased metastasis in tumors
driven by polyoma middle T antigen in SRC1-/- mice
[30]. To understand how coactivator proteins regulate
response to nuclear hormone receptor ligands such as
PPAR and RXR we examined neu oncogene driven
mammary tumorigenesis in mice lacking SRC-1. We
also used a targeted gene approach in human breast
cancer cell lines overexpressing SRC-1. SRC-1 null
mutation in mice overexpressing the neu oncogene in
mammary epithelium significantly increased the tumor
latency period, reduced tumor proliferation index and
metastasis, inhibited response to PPAR and RXR ligands,
and induced differentiation specific gene expression.
Coactivator overexpression in human breast cancer cell
lines increased proliferation with resistance to PPAR
and RXR ligands and remodeled chromatin of the proxi-
mal epidermal growth factor receptor promoter, which
is a principal growth signaling pathway in mammary
epithelial cells. These results indicate that SRC-1 expres-
sion plays key roles in mammary tumorigenesis and
response to anti-proliferative therapies.
Methods
Transgenic Mouse Procedures
Animal procedures were approved by the institutional
animal care committee. SRC1-/- mice (15) were crossed
with the mammary tumor prone MMTV-neu transgenic
strain in the FVB background (The Jackson Laboratory).
These offspring were bred back to the SRC1-/- strain to
create SRC1-/- mice harboring the neu proto-oncogene.
MMTV-neu mice were also bred with SRC1+/+ control
mice. Mice were genotyped by PCR analysis of tail DNA
samples. Mice were given P.O. doses of 100 mg/kg clofi-
brate, ciglitazone, AGN194204, or vehicle in corn oil
daily for 8 weeks (20 mice/group). The mammary gland
chains of female mice were examined visually and by
palpation twice weekly. Tumors were measured twice
weekly using calipers. Mice were euthanized when
tumors reached 2 cm in largest dimension. Tumor tis-
sue was processed for histopathologic and gene expres-
sion analyses. Statistical analysis was determined by
ANOVA.
Histopathology and Immunohistochemistry
Tumor tissue was fixed in formalin for 16 hours at room
temperature. Tissue was dehydrated in an ethanol series fol-
lowed by clearing in xylene and embedding in paraffin.
Seven micrometer sections were cut from the blocks and
placed on poly-L-lysine coated slides. Sections were depar-
affinized in xylene and stained with hematoxylin and eosin
for histopathologic interpretation. For immunohistochemis-
try, sections were rehydrated and blocked with 10% normal
serum followed by incubation with anti-PCNA antibody for
one hour at room temperature. After washing in PBS, the
sections were incubated with anti-mouse IgG secondary
antibody conjugated to biotin for 10 minutes at room tem-
perature. After additional washing in PBS, the cultures were
incubated with streptavidin conjugated horseradish peroxi-
dase enzyme for 10 minutes at room temperature. Follow-
ing final washes in PBS, antigen-antibody complexes were
detected by incubation with hydrogen peroxide substrate
solution containing aminoethylcarbazole chromogen
reagent. Immunohistochemical results were photographed
using light microscopy. The percentage of PCNA positive
cells were determined by counting cells in 10 random
high power fields. Statistical significance was determined by
tt e s t .
Han and Crowe BMC Cancer 2010, 10:629
http://www.biomedcentral.com/1471-2407/10/629
Page 2 of 14Gene Expression Profiling
Total RNA was extracted from SRC1+/+ and SRC1-/-
tumors using a commercially available kit (RNEasy, Qia-
gen, Valencia, CA). Integrity of ribosomal RNA bands
was confirmed by northern gel electrophoresis. Total
RNA (10 μg) was converted to labeled cRNA targets.
The biotinylated cRNA targets were then purified, frag-
mented, and hybridized to GeneChip mouse genome
430 2.0 expression arrays (Affymetrix, Santa Clara, CA)
to interrogate the abundance of 39,000 possible tran-
scripts in each sample. Affymetrix GCOS software was
used to generate raw gene expression scores and nor-
malized to the relative hybridization signal from each
experiment. All gene expression scores were set to a
minimum value of 2 times the background determined
by GCOS software in order to minimize noise associated
with less robust measurements of rare transcripts. Nor-
malized gene expression data was imported into dChip
software http://www.biostat.harvard.edu/complab/dchip
for hierarchical clustering analysis using the average
linkage algorithm. Data was analyzed by t test with p <
0.005 followed by ratio analysis (minimum 2 fold
change).
Cell Culture and Stable Transfection
The human breast cancer cell lines used in this study
were purchased from the American Type Culture Col-
lection and cultured in Dulbecco’s modified Eagle med-
ium, 10% fetal bovine serum, and 40 μg/ml gentamicin
in a humidified atmosphere of 5% CO2 at 37°C. Cultures
were treated with 100 μM clofibrate (PPARa selective
agonist), ciglitazone (PPARg selective agonist), or 100
nM AGN194204 (RXR selective agonist; kindly provided
by Dr. Roshantha Chandraratna) or vehicle for up to 24
hours. MCF7 and MDA-MB-468 cells were transfected
with 2 μg SRC-1, CBP, or neomycin resistance plasmid
using Lipofectamine according to manufacturer’s recom-
mendations (Invitrogen). Cells were selected in 400 μg/ml
G418 for 14 days. Resistant clones were picked for expan-
sion and characterization.
Cell Proliferation Analysis
Triplicate cultures of 3 × 10
4 p a r e n t a l ,S R C - 1 ,C B P ,o r
vector control clones were plated into six well plates
and treated with 100 μM clofibrate or ciglitazone, 100
nM AGN194204, or vehicle alone or in combination for
6 days. Cultures were trypsinized and counted at 2 day
intervals using a hemacytometer.
Western Blot
Protein was extracted in 1× Laemmli buffer from human
breast cancer cell lines and clones treated with PPAR or
RXR ligands. Seventy-five μg total cellular protein was
separated by SDS-PAGE on 10% resolving gels under
denaturing and reducing conditions. Separated proteins
were electroblotted to PVDF membranes according to
manufacturer’s recommendations (Roche Applied
Science). Blots were incubated with antibodies to
PPARs, RXRa,S R C - 1 ,C B P ,E G F R ,E R K 1 ,c - m y c ,c y c l i n
A, cyclin E, cdk1, cdk4, casein, WAP, or b-actin for 16
hours at 4°C. After washing in Tris buffered saline con-
taining 0.1% Tween 20 (TBST, pH 7.4), blots were incu-
bated for 30 minutes at room temperature with anti-IgG
secondary antibody conjugated to horseradish peroxi-
dase. Following extensive washing in TBST, bands were
visualized by the enhanced chemiluminescence method
(Roche Applied Science). Bands were quantitated by
laser densitometry.
Chromatin Immunoprecipitation
Parental and neomycin resistant MCF7 and MDA-MB-
468 human breast cancer cells and those overexpressing
SRC-1 or CBP proteins were treated with 100 μM clofi-
brate or ciglitazone, 100 nM AGN194204, or vehicle for
24 hours. After washing in PBS, cells were fixed in 1%
formaldehyde for 10 minutes at room temperature. Cells
were washed in PBS and lysed in immunoprecipitation
buffer containing protease inhibitors for 30 minutes at
4°C, sheared, and centrifuged at 10,000 × g for 10 min-
utes. Supernatants were cleared with 2 μg sheared sal-
mon sperm DNA, 20 μl preimmune serum, and 20 μl
protein A/G sepharose beads for 2 hours at 4°C. Ali-
quots of the supernatant were used as input DNA for
normalization. Immunoprecipitation using anti-SRC-1,
anti-CBP, or anti-acetylated histone H3 antibodies
(Santa Cruz Biotechnology) was performed overnight at
4 ° C .P r e i m m u n eI g Gw a su s e da st h en e g a t i v ec o n t r o l
antibody. Immunoprecipitates were washed extensively
in immunoprecipitation buffer, resuspended in 10 mM
Tris-HCl, 1 mM EDTA (TE, pH 8) and incubated at 65°C
for 6 hours to reverse crosslinks. The supernatants were
extracted with phenol/chloroform and ethanol precipi-
tated. Following washing in 70% ethanol, pellets were
dried and suspended in 50 μl TE. For real time PCR, 1 μl
of template was amplified in buffer containing 10 mM
Tris-HCl (pH 8.3), 50 mM KCl, 2.5 mM MgCl2, 200 nM
each dNTP, and 100 ng each primer (5’-GCCTCC
GCCCCCCGCACGGTG-3’ and 5’-CGCTGCTCCCC
GAAGAGCTCG-3’) flanking the proximal EGFR promo-
ter (-221 bp to -1 bp; 30). The optimized cycle para-
meters were one cycle at 94°C for 3 minutes followed by
25 cycles of 94°C for 25 seconds, 58°C for 60 seconds, 72°
C for 60 seconds, and one final cycle at 72° for 10 min-
utes (iCycler, Bio-Rad).
Nucleosomal Mapping
Nuclei were isolated from parental human breast cancer
cell lines MCF7 and MDA-MB-468 and coactivator
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or ciglitazone, 100 nM AGN194204, or vehicle for
24 hours. Chromatin was digested to mononucleosomal
form with micrococcal nuclease (Roche Applied
Science). The digestion was stopped by addition of
50 mM EDTA. Nuclei were lysed in 1% SDS and treated
with 0.1 mg proteinase K overnight at 37°C. DNA was
purified by phenol/chloroform extraction and ethanol
precipitation. DNA was suspended in TE buffer and
analyzed by agarose gel electrophoresis to ensure diges-
tion to mononucleosomal fragments. These fragments
are eluted from the gel and used as PCR templates to
determine nucleosomal occupancy of the proximal
EGFR promoter as described in the preceding section.
Undigested genomic DNA was used as the positive con-
trol and template free samples were used as the negative
control.
Transient Transfection and Promoter Activation
Triplicate cultures of 50% confluent MCF-7 or MDA-
MB-468 cells were transiently transfected with 5 μgo f
the human EGFR promoter/reporter vectors along with
2 μgS R C - 1 ,C B P ,o rb l a n ke x p r e s s i o np l a s m i d su s i n g
Lipofectamine according to the manufacturer’s recom-
mendations (Invitrogen). One μg b-galactosidase expres-
sion plasmid was used to normalize for transfection
efficiency. Cultures were treated with 100 μMc l o f i b r a t e
or ciglitazone, 100 nM AGN194204, or vehicle for 24
hours. Cells were harvested and reporter gene activity
determined using a commercially available kit and lumin-
ometer (Applied Biosystems). Luciferase activity was nor-
malized to b-galactosidase levels for each sample.
Statistical significance was determined by ANOVA.
Reverse Transcription-Polymerase Chain Reaction
RNA was extracted from SRC-1 and CBP clones using a
commercially available kit (Qiagen) and reverse tran-
scribed using SuperScript II reverse transcriptase
according to manufacturer’s instructions (Invitrogen).
cDNA was amplified using specific primers (PPARa 5’-
TGACCTGGCCCTATTCATTG-3’ and 5’-GTAGATC
TCCTGGAGCAGAG-3’; PPARg 5’-TTTGCTGAATGT-
GAAGCCC-3’ and 5’-GTGAAGACTCATGTCTGTC
TC-3’;R X R a 5’-TCTTTAACCCTGACTCCAAGG-3’
and 5’-GCCTCCAGCATCTCCATAAG-3’; CBP 5’-CAC
ACCCACACACATCTATC-3’ and 5’-ACAAAAAACCC
CGAACACTAAG-3’;S R C - 15 ’-ACTGCAACCAGCT
CTCATCC-3’ and 5’-TTGCTCCAAATGCTACGACC-
3’)i n2 0m MT r i s - H C l( p H8 . 3 ) ,1 . 5m MM g C l 2,
63 mM KCl, 0.05% Tween 20, 1 mM EGTA, 50 μMo f
each dNTP, and 2.5 U Taq DNA polymerase (Roche
Applied Science). Amplification with b-actin cDNA
using primers 5’-ACAGGAAGTCCCTTGCCATC-3’
and 5’-ACTGGTCTCAAGTCAGTGTACAGG-3’ as the
internal control was carried out by real time PCR
(iCycler, Bio-Rad) using cycle parameters 94°C for 25
seconds, 55°C for 1 minute, and 72°C for 1 minute.
Results
SRC-1 knockout animals are viable and fertile [15]. To
examine the effects of SRC-1 null mutation on mam-
mary tumorigenesis in vivo, we created SRC1-/-;neu and
SRC1+/+;neu mice and characterized mammary tumors
arising in these animals following administration of
PPAR or RXR ligands. The gross appearance of mam-
mary tumors in vivo is shown in Figure 1A. Neither the
SRC-1 null mutation nor ligand treatment affected the
histopathologic pattern of these tumors (Figure 1B, C).
Tumors showed abnormal ducts containing secretory
products separated by sheets of poorly differentiated
epithelial cells. This pattern was similar to poorly differ-
entiated adenocarcinoma in human breast cancer
(Figure 1D) as previously reported for MMTV-neu mice
[31]. Very early stage tumors (prior to detection by pal-
pation) also demonstrated a histopathologic pattern con-
sistent with poorly differentiated adenocarcinoma
(Figure 1E, F). The histopathologic appearance of meta-
static tumors in the lungs of SRC1+/+;neu and SRC1-/-;
neu mice was consistent with poorly differentiated ade-
nocarcinoma (Figure 1G, H). The SRC-1 null mutation
dramatically increased the mean tumor latency period in
t h e s em i c ec o m p a r e dt oc o n t r o l s( 6 0v s .3 8w e e k s ;p<
10
-10; Figure 1I). Treatment with AGN194204 extended
t h et u m o rl a t e n c yp e r i o dt o4 8w e e k si nS R C 1 + / +m i c e
(p < 0.001). Clofibrate and ciglitazone treatment
extended the latency period to 41 and 42 weeks respec-
tively in SRC1+/+ mice (p < 0.05 for ciglitazone). The
increased tumor latency period due to ligand treatment
was not observed in SRC1-/- mice, indicating that SRC-
1 was important for these effects. SRC1-/-mice had sig-
nificantly fewer metastatic tumors than SRC1+/+ ani-
mals (80% reduction; p < 0.002; Figure 1J). Treatment
with AGN194204, clofibrate, and ciglitazone reduced
the number of metastatic tumors in SRC1+/+ mice (20-
80% reduction; p < 0.02). No statistically significant dif-
ferences in growth rates or number of tumors were
observed between the groups. These results indicate that
SRC-1 null mutation increased mammary tumor latency,
decreased metastasis, and reduced the inhibitory effects
of PPAR and RXR ligands in neu transgenic mice.
Despite the distinct biological differences between
SRC1-/-;neu and SRC1+/+;neu mammary tumors, there
were no apparent histopathologic changes reflective of
t h ec h a n g ei np h e n o t y p e .T h i sf i n d i n gi ss i m i l a rt o
human breast cancer in which tumors with similar his-
topathologic diagnoses often manifest different clinical
behaviors [32]. This issue has subsequently been
addressed by classifying tumors according to their global
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Page 4 of 14Figure 1 Increased tumor latency and decreased metastasis in oncogene induced mammary tumors from SRC-1 null mutant mice. (A)
Mammary tumor formation (at left) in the MMTV-neu mouse. (B, C) The histopathologic appearance of mammary tumors from the SRC1-/-;neu
mouse resembles poorly differentiated adenocarcinoma in humans. Hematoxylin and eosin stained sections are shown. Scale bars 100 μm and
50 μm respectively. (D) Histopathologic appearance of human poorly differentiated adenocarcinoma stained with hematoxylin and eosin. Scale
bar = 50 μm. (E, F) Histopathologic appearance of early mammary tumors (prior to detection by palpation) in SRC1+/+;neu and SRC1-/-;neu
mice is consistent with poorly differentiated adenocarcinoma. Scale bar = 100 μm. (G, H) Histopathologic appearance of SRC1+/+;neu and
SRC1-/-;neu mammary tumor lung metastases is consistent with poorly differentiated adenocarcinoma. Scale bars = 50 μm. (I) Increased tumor
latency in SRC1-/-;neu mice compared to SRC1+/+;neu animals. Mice of both genotypes were treated with AGN194204 (AGN), clofibrate (clo), or
ciglitazone (cig) as described in Materials and Methods. The mammary gland chains of mice were examined weekly by palpation to detect
tumors. (J) Decreased mammary tumor metastasis in SRC1-/- mice. SRC1+/+;neu and SRC1-/-;neu mice were treated with 100 mg/kg
AGN194204, clofibrate, or ciglitazone as described in Materials and Methods. The number of metastatic lung lesions was counted at necropsy in
each group of mice. (K) Loss of SRC-1 expression inhibits proliferation index in oncogene induced mammary tumors. Tumor sections from SRC1
+/+;neu and SRC1-/-;neu were subjected to immunohistochemistry using anti-PCNA antibody. These experiments were performed 3 times with
similar results. Representative sections are shown.
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matic effects of the SRC-1 null mutation on inhibition of
mammary tumorigenesis in the neu transgenic mouse,
we performed global gene expression profiling of tumors
from SRC1+/+ and SRC1-/- animals. We identified 237
differentially expressed genes meeting the criteria of p <
0.005 and minimum 2 fold change in expression. As
shown in Table 1, SRC1-/- tumors expressed higher
mRNA levels of the cyclin dependent kinase inhibitors
p21 and p15 (8.8 fold and 8.5 fold increases respectively).
Inhibitors of epithelial cell proliferation such as
transforming growth factor beta 2 were upregulated in
SRC1-/- tumors (5.2 fold). These changes in expression
of inhibitors of cell cycle progression may help explain
the increased latency period in SRC1-/- tumors. To con-
firm these results, we examined the proliferation index in
SRC1-/- and SRC1+/+ tumors by anti-PCNA immuno-
histochemistry. As shown in Figure 1K, SRC1-/- tumors
showed significantly decreased numbers of PCNA posi-
tive cells compared to SRC1+/+ cancers (6% vs. 70%; p <
0.0002). SRC1-/- tumors also highly expressed differen-
tiation markers (parotid secretory protein, 313.4 fold;
Table 1 Differentially expressed genes between SRC1+/+ and SRC1-/- mammary tumors (237 genes)
Accession Gene symbol Gene name fold change
BC010288 Psp parotid secretory protein 313.4
NM_007446 Amy1 amylase 1, salivary 242.1
BC011134 Chia chitinase, acidic 226.6
NM_011422 Smr1 submaxillary gland androgen regulated protein 209.7
NM_008843 Pip prolactin induced protein 71.9
AF108501 Clca1 chloride channel calcium activated 1 42.7
BG862223 Camk2b Calcium/calmodulin-dependent protein kinase II, b 39.5
NM_009323 Tbx15 T-box 15 38.3
NM_009638 Crisp1 cysteine-rich secretory protein 1 35.4
BB795585 Ntrk2 neurotrophic tyrosine kinase, receptor, type 2 21.7
NM_013605 Muc1 mucin 1, transmembrane 17.2
BF119305 Csn1s2a casein alpha s2-like A 13.8
NM_008109 Gdf5 growth differentiation factor 5 10.9
NM_053134 Pcdhb9 protocadherin beta 9 9.7
AK007630 Cdkn1a cyclin-dependent kinase inhibitor 1A (p21) 8.8
AF059567 Cdkn2b cyclin-dependent kinase inhibitor 2B (p15) 8.5
BF683028 Gyk glycerol kinase 7.2
NM_011709 Wap whey acidic protein 7.1
C86550 Dcpp demilune cell and parotid protein 6.7
NM_007554 Bmp4 bone morphogenetic protein 4 6.1
BF456404 Pak1 p21 (CDKN1A)-activated kinase 1 5.4
AV246759 Tgfb2 transforming growth factor, beta 2 5.2
NM_007865 Dll1 delta-like 1 (Drosophila) 5.0
NM_010669 Krt6b Keratin 6B 5.0
BQ032637 Jak1 Janus kinase 1 -3.5
BG064038 Arhgap12 Rho GTPase activating protein 12 -3.5
BC021401 Muc10 mucin 10, submandibular gland salivary mucin -3.9
AK020693 Acpp acid phosphatase, prostate -4.1
BB524685 Tmprss11a transmembrane protease, serine 11a -5.6
NM_009973 Csn1s2b casein alpha s2-like B -5.9
U82380 Smr2 submaxillary gland androgen regulated protein 2 -6.0
NM_013655 Cxcl12 chemokine (C-X-C motif) ligand 12 -6.4
BF011461 Rbbp4 retinoblastoma binding protein 4 -6.4
BB745167 Ppargc1a PPAR, gamma, coactivator 1 alpha -7.2
NM_011271 RNase 1 ribonuclease, RNase A family, 1 (pancreatic) -9.4
BB760085 Eya1 eyes absent 1 homolog (Drosophila) -9.4
AV334599 Tcfap2b transcription factor AP-2 beta -33.6
AV275795 Plb1 phospholipase B1 -47.4
BC021770 Cldn10 claudin 10 -81.2
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71.9 fold; casein alpha s2-like A, 13.8 fold; whey acidic
protein, 7.1 fold; demilune cell and parotid protein, 6.7
fold). These data indicate that SRC1-/- mammary tumors
are less proliferative and more differentiated with respect
to gene expression than SRC1+/+ cancers.
We also determined the effects of SRC-1 on PPAR
and RXR mediated proliferation of human breast cancer
cell lines. We previously demonstrated that human
breast cancer cell lines expressed PPARa and PPARg,
and their lipid ligands inhibited proliferation of these
cells [22]. We examined expression of PPARs, RXRa,
and their coactivators SRC-1 and CBP by quantitative
RT-PCR in human breast cancer cell lines. As shown in
Figure 2A, PPARg was expressed at highest levels in
human breast cancer cell lines. PPARa was expressed at
4-5 fold lower levels in these lines. RXRa was expressed
at levels similar to that of PPARa. SRC-1 was expressed
at levels 10 fold lower than PPARg and CBP mRNA was
expressed at lowest levels in these lines. By western
blotting, we determined PPAR, RXRa, coactivator, and
cell cycle regulatory protein expression in human breast
cancer cell lines. As shown in Figure 2B, PPARg protein
was expressed at highest levels in human breast cancer
cell lines. PPARa and RXRa were expressed at lower
levels, while SRC-1 and CBP expression was barely
detectable by western blot. To examine potential syner-
gistic effects of synthetic PPAR and RXR ligands on
these lines, we treated human breast cancer cells with
the PPARa agonist clofibrate, the PPARg selective ligand
ciglitazone, and the RXR selective agonist AGN194204.
These agents inhibited proliferation of all four cell lines
tested (MCF7, T47 D, MDA-MB-231, MDA-MB-468).
As shown in Figure 2C and 2D, clofibrate and
AGN194204 as single agents inhibited MCF7 and
MDA-MB-468 cell proliferation by 20%. Ciglitazone was
am o r ee f f e c t i v ei n h i b i t o ro fp r o l i f e r a t i o na sas i n g l e
agent than the other two compounds (45-50% fewer
cells compared to control cultures). The combination of
clofibrate and AGN194204 produced an additive effect
on inhibition of breast cancer cell proliferation (40%
fewer cells compared to control cultures). The combina-
tion of ciglitazone and AGN194204 was the most effec-
tive inhibitor of proliferation (55-60% fewer cells
compared to control cultures). Cytologic features of pro-
grammed cell death (cellular condensation and round-
ing, membrane blebbing) were not observed during
treatment with these ligands. These results indicate that
PPAR and RXR selective ligands are effective inhibitors
of breast cancer cell proliferation in vitro.
To determine which cell cycle regulators were
involved in inhibition of breast cancer cell proliferation
by PPAR and RXR ligands, we treated 4 lines individu-
ally with these ligands and examined protein expression
by western blot. As shown in Figure 2E, expression of
EGFR, c-myc, and cyclin A was inhibited by PPAR and
RXR ligands in MCF7 cells (up to 10 fold, 4 fold, and 5
fold respectively). Expression of other cell cycle regula-
tory proteins such as ERK1 was not affected in MCF7
cells. In T47 D cells, expression of ERK1, c-myc, cyclin
A, cdk1 and cdk4 proteins were inhibited by PPAR and
RXR ligands (4 fold, 10 fold, 11 fold, 5 fold, and 4 fold
respectively). In MDA-MB-231 cells, expression of
EGFR, ERK1, cyclin E, cdk1, and cdk4 proteins were
i n h i b i t e d( 4f o l d ,2f o l d ,1 5f o l d ,2f o l d ,a n d4f o l d
respectively) by these ligands. In MDA-MB-468 cells,
expression of EGFR, ERK1, c-myc, cyclin A, cdk1, and
cdk4 proteins were inhibited (20 fold, 3 fold, 14 fold, 9
fold, 6 fold, and 3 fold respectively) by PPAR and RXR
selective ligands. These results indicate that PPAR and
RXR ligands inhibit multiple overlapping cell cycle regu-
latory proteins in human breast cancer cell lines.
Given that nuclear receptors such as PPARs and RXRs
mediate control of gene expression via recruitment of
coactivator proteins from other transcription factor
binding sites such as AP-1 [11], we examined interac-
tion of CBP and SRC-1 histone acetyltransferases within
the proximal EGFR promoter, which contains three AP-
1 sites by chromatin immunoprecipitation [33]. As
shown in Figure 2F and 2G, treatment of MCF7 or
MDA-MB-468 cells with PPAR or RXR ligands reduced
SRC-1 occupancy of the proximal EGFR promoter by
70-80%. These ligands also reduced CBP occupancy of
the promoter by 60-80%. Consistent with this loss of
interaction with histone acetyltransferases, acetylation of
histone H3 in the proximal EGFR promoter was reduced
by 65-75% following treatment with PPAR and RXR
ligands. Relative nucleosomal occupancy of the proximal
EGFR promoter increased 2-4 fold in cells treated with
PPAR or RXR ligands. These changes in chromatin were
consistent with loss of EGFR expression and inhibition
of proliferation in MCF7 and MDA-MB-468 cells trea-
ted with these ligands. These results indicate that PPAR
and RXR ligands inhibit interaction of coactivator pro-
teins with key growth regulatory genes such as EGFR.
G i v e nt h a tP P A Ra n dR X Rl i g a n d - m e d i a t e dl o s so f
SRC-1 and CBP occupancy in the proximal EGFR pro-
moter correlated with decreased expression of the
receptor, we wished to determine if coactivator overex-
pression could counteract effects of the ligands. As
shown in Figure 2H and 2I, treatment of MCF7 or
MDA-MB-468 cells with AGN194204 or clofibrate
inhibited activity of the transiently transfected EGFR
promoter by 25-30%. Ciglitazone treatment or the com-
bination of clofibrate and AGN194204 further inhibited
EGFR promoter activity to 40-50% less than control
levels. The combination of ciglitazone and AGN194204
inhibited EGFR promoter activity by 60-70%. However
Han and Crowe BMC Cancer 2010, 10:629
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Page 7 of 14Figure 2 PPAR and RXR ligands inhibit human breast cancer cell proliferation in vitro. (A) Expression of SRC-1, CBP, RXRa,a n dP P A R
mRNA in human breast cancer cell lines. (B) Expression of SRC-1, CBP, RXRa, and PPAR proteins in human breast cancer cell lines. (C, D).
Triplicate cultures of MCF7 or MDA-MB-468 cells were treated with 100 μM of the PPARa agonist clofibrate (clo) or the PPARg agonist ciglitazone
(cig) alone or in combination with 100 nM of the RXR selective compound AGN194204 or vehicle for 6 days. At 2 day intervals, cells were
trypsinized and counted using a hemacytometer. Error bars represent SEM of 3 independent experiments. (E) Human breast cancer cell lines
MCF7, T47 D, MDA-MB-231, and MDA-MB-468 were treated with 100 nM AGN194204, 100 μM ciglitazone (cig) or clofibrate (clo), or vehicle for 16
hours. Protein extracts from these treated cells were subjected to western blotting using cell cycle antibodies indicated at left. These
experiments were performed 3 times with similar results. (F, G) PPAR and RXR ligands inhibit coactivator occupancy of the proximal EGFR
promoter. MCF7 or MDA-MB-468 cells were treated with 100 nM AGN194204, 100 μM ciglitazone (cig) or clofibrate (clo), or vehicle for 16 hours
followed by chromatin immunoprecipitation (ChIP) with antibodies to SRC1, CBP, or acetylated histone H3 (acH3). Nuclease digested DNA from
treated cells was amplified to detect nucleosomal loading of the EGFR promoter. The proximal promoter region was amplified by quantitative
PCR and amplification products normalized to input DNA. (H, I) SRC-1 overexpression blocks PPAR and RXR ligand mediated suppression of EGFR
promoter activity. The EGFR-luc promoter/reporter vector was transiently transfected with SRC-1, CBP, or control expression vectors into triplicate
cultures of MCF7 or MDA-MB-468 cells. Cultures were treated with AGN194204, clofibrate, or ciglitazone alone or combination. Luciferase activity
was determined as described in Materials and Methods. Error bars indicate SEM of 3 independent experiments.
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Page 8 of 14when SRC-1 was transfected with the EGFR reporter
construct, promoter activity was induced to 180% of
control levels. CBP expression induced EGFR promoter
activity to 270% of control levels. Coactivator overex-
pression completely blocked the inhibitory effects of
PPAR and RXR ligands. These results indicate that
coactivators can induce resistance to inhibition of EGFR
promoter activity by nuclear receptor ligands.
To examine the effects of SRC-1 and CBP on breast
cancer cell phenotype and gene expression, we created
stable clones expressing these coactivators. Relative
mRNA expression of SRC-1 and CBP in stable MCF7
and MDA-MB-468 clones is shown in Figure 3A and
3B. SRC-1 or CBP expression was increased by 2-6 fold
when compared to neomycin resistant control clones.
We also examined expression of SRC-1 and CBP pro-
teins in these clones (Figure 3C). To determine the
effects of coactivator overexpression on the chromatin
organization of the proximal EGFR promoter, we per-
formed chromatin immunoprecipitation using genomic
DNA from stable clones. As shown in Figure 3D-G,
PPAR and RXR ligands failed to recruit SRC-1 or CBP
from the EGFR promoter in MCF7 and MDA-MB-468
cells overexpressing these coactivators. This was in
marked contrast to the coactivator recruitment observed
in parental cell lines and neomycin resistant control
clones. PPAR and RXR ligands also failed to inhibit
acetylation of histone H3 in the proximal EGFR promo-
ter in SRC-1 or CBP overexpressing clones. Minimal
nucleosomal DNA was amplified from these clones,
indicating an open and transcriptionally permissive
chromatin structure at the proximal EGFR promoter.
These results indicated that SRC-1 and CBP acetylate
histones in the proximal EGFR promoter, which corre-
lated with resistance to PPAR and RXR ligands. To cor-
relate these coactivator mediated changes with
alterations in cell cycle regulatory genes, we examined
protein expression by western blot. As shown in Figure
3H, MCF7 clones overexpressing SRC-1 and CBP
showed no decreases in expression of EGFR, ERK1, c-
myc, cdk1, and cdk4 in response to PPAR and RXR
ligands as observed in parental cell lines and control
clones. A slight reduction of cyclin A expression in
response to retinoid and ciglitazone treatment was
detected was observed in MCF7 clones. Overall similar
results were observed in MDA-MB-468 clones. We also
examined protein expression of the differentiation mar-
kers casein and WAP in SRC-1 and CBP overexpressing
clones. SRC-1 and CBP overexpression dramatically
inhibited expression of the differentiation marker casein
by up to 16 fold in MCF7 clones (Figure 3I). Casein
expression was not detected in MDA-MB-468 cells, nor
was WAP protein expression observed in these clones
by western blot. These results indicate that coactivator
overexpression inhibits PPAR and RXR ligand mediated
reductions in cell cycle regulatory gene expression.
We also determined the effects of coactivators on
breast cancer cell proliferation. Both SRC-1 and CBP
stable clones exhibited increased proliferation in vitro
compared to MCF7 and MDA-MB-468 control clones
(Figure 4A). SRC-1 overexpression increased cell num-
bers after 6 days culture by 60%. CBP stable clones
exhibited 120% greater cell numbers after 6 days culture
compared to control clones. PPAR and RXR ligands
individually and in combination inhibited MCF7 and
MDA-MB-468 control clone proliferation by 20-50%
after 2 days treatment (Figure 4B, C). In contrast, PPAR
and RXR ligands did not significantly inhibit cellular
proliferation in SRC-1 and CBP stable clones. We con-
cluded that coactivator overexpression increased breast
cancer cell proliferation and blocked the inhibitory
effects of PPAR and RXR ligands.
Discussion
The results of our present study demonstrated that
selective activation of PPARs and RXRs inhibits prolif-
eration of human breast cancer cell lines in vitro. This
inhibition of proliferation is reflected in decreased
expression of cell cycle regulatory genes in treated
breast cancer lines. These results extend the findings of
our previous study using PPAR lipid ligands [22]. The
large number of diverse PPAR ligands has produced
pleiotropic effects in human breast cancer cell lines and
animal tumor models. PPARg ligands inhibited prolifera-
tion of human breast cancer cell lines in vitro [34], but
individual lines may respond differently to the same
drug [35]. PPARa activation by clofibrate has been
shown to increase proliferation of breast cancer cells
and of normal rat mammary gland in vivo [36,37]. How-
ever, both troglitazone (a PPARg ligand) and clofibrate
inhibited carcinogen induced mammary tumors in rats,
in agreement with our results [38]. A previous study
also showed that selective PPAR activation regulated
histopathologic differentiation of mammary tumors [39].
While we did not observe changes in histopathologic
pattern as the result of PPAR ligand exposure in the
MMTV-neu mouse model, loss of SRC-1 produced
increased expression of differentiation markers in these
mammary tumors (see below).
Members of the EGFR gene family have been targets
of molecular therapy for breast cancer. The results of
our study indicated that EGFR is a target gene for PPAR
and RXR antiproliferative therapy. Inhibition of the
EGFR gene in human breast cancer cells is likely due to
recruitment of CBP and SRC-1 from the EGFR promo-
ter by ligand activated PPARs and RXRs. This recruit-
ment correlates with decreased histone acetylation and
nucleosome formation on the proximal EGFR promoter.
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Page 9 of 14Figure 3 Coactivator overexpression induces resistance to the anti-proliferative effects of PPAR and RXR ligands. (A, B) Expression of
SRC-1 and CBP mRNAs in stable MCF7 and MDA-MB-468 clones is shown by quantitative RT-PCR. Coactivator expression is normalized to levels
of b-actin mRNA. Error bars indicate SEM of 3 independent experiments. (C) Expression of SRC-1 and CBP proteins in human breast cancer
clones. (D, E) MCF7 or MDA-MB-468 cells overexpressing SRC- 1 were treated with 100 nM AGN194204, 100 μM ciglitazone (cig) or clofibrate
(clo), or vehicle for 16 hours followed by chromatin immunoprecipitation (ChIP) with antibodies to SRC1, CBP, or acetylated histone H3 (acH3).
Nuclease digested DNA from treated cells was amplified to detect nucleosomal loading of the EGFR promoter. The proximal promoter region
was amplified by quantitative PCR and amplification products normalized to input DNA. (F, G) MCF7 or MDA-MB-468 cells overexpressing CBP
were treated with 100 nM AGN194204, 100 μM ciglitazone (cig) or clofibrate (clo), or vehicle for 16 hours followed by chromatin
immunoprecipitation (ChIP) with antibodies to SRC1, CBP, or acetylated histone H3 (acH3). Nuclease digested DNA from treated cells was
amplified to detect nucleosomal loading of the EGFR promoter. The promoter region was amplified by quantitative PCR. (H) MCF7 (left panel)
and MDA-MB-468 (right panel) cells stably expressing SRC-1 or CBP were treated with 100 μM clofibrate (clo) or ciglitazone (cig), 100 nM
AGN194204, or vehicle for 16 hours. Protein extracts from these treated cells were subjected to western blotting using cell cycle antibodies
indicated at left. These experiments were performed 3 times with similar results. (I) SRC-1 and CBP overexpression inhibits casein protein levels in
human breast cancer cells. Protein extracts from MCF7 and MDA-MB-468 clones expressing SRC-1 or CBP or control vector were subjected to
western blotting using antibodies indicated at left.
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Page 10 of 14In contrast, overexpression of SRC-1 or CBP induced
resistance to the antiproliferative effects of PPAR and
RXR ligands and blocks inhibition of EGFR expression
by these compounds. Overexpression of the coactivator
SRC-3 enhanced estrogen stimulated proliferation and
blocked inhibition by anti-estrogens in human breast
cancer cell lines [40]. SRC-1 or CBP overexpression
increased proliferation of human breast cancer cell lines,
which correlated with increased histone acetylation and
loss of nucleosome formation on the EGFR promoter.
Interestingly overexpression of either SRC-1 or CBP
produced increased occupancy of the EGFR promoter
by the other coactivator. In support of these findings,
CBP and SRC-1 have been shown to synergistically
interact to increase gene transcription [41]. In vivo,
increased SRC-1 and EGFR expression was demon-
strated in post-lactating rat mammary gland [42]. Con-
versely SRC-1 deficiency resulted in decreased hormone
response in the null mutant mouse [15,16].
We also reported the effects of SRC-1 null mutation
on mammary tumorigenesis in the MMTV-neu trans-
genic mouse. Loss of SRC-1 expression dramatically
increased tumor latency in this model, which correlated
with decreased proliferation index and upregulation of
cell cycle inhibitors such as transforming growth factor
b2 (5.2 fold), Cdkn1a (8.8 fold), and Cdkn2b (8.5 fold).
Global gene expression profiling of these tumors
revealed increased expression of differentiation markers,
such as parotid secretory protein, salivary amylase 1,
submaxillary gland androgen regulated protein, prolactin
induced protein, cysteine rich secretory protein 1, whey
acidic protein, and demilune cell and parotid protein.
Upregulation of these genes indicate that SRC1-/- mam-
mary tumors are more differentiated than their SRC1+/+
counterparts. Loss of SRC1 had differential effects on
some classes of genes, such as upregulation of mucin 1
and casein alpha s2-like A (17.2 and 13.8 fold respec-
tively) but downregulation of mucin 10 and casein alpha
Figure 4 Coactivator overexpression increases proliferation and resistance to PPAR ligands in human breast cancer cell lines.( A )
Triplicate cultures of stable CBP and SRC-1 expressing clones were grown in vitro for 6 days and compared to proliferation rates of neomycin
resistant control cells (neo). Error bars indicate SEM of 3 independent experiments. (B, C) SRC-1, CBP, and neomycin resistant (neo) stable MCF7
or MDA-MB-468 clones were treated with 100 μM clofibrate (clo) or ciglitazone (cig) alone or in combination with 100 nM AGN194204 and
grown in vitro for 6 days. Cells were counted with a hemacytometer. Error bars indicate SEM of 3 independent experiments.
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Page 11 of 14s2-like B (-3.9 and -5.9 fold). Interestingly a tissue speci-
fic knockout of PPARg altered the lipid composition of
mammary gland secretions with deleterious effects on
neonatal mice [43]. Taken together, these results suggest
that SRC-1 is a key regulator of gene products compris-
ing mammary secretions. While expression of differentia-
tion genes are not routinely determined in clinical cases
of human breast cancer, Her2/neu and estrogen receptor
levels are often used to determine if patients should be
treated with targeted therapies against these gene
products.
Expression of genes commonly altered in human
breast cancer was also changed in SRC1-/- mouse mam-
mary tumors. Bone morphogenetic protein 4 stimulates
outgrowth of normal mammary buds [44], is upregu-
lated in human breast cancer [45], and was increased by
6.1 fold in the SRC1-/- tumor model. However the role
of bone morphogenetic protein 4 in human breast can-
cer is not clear, producing opposing effects on different
human breast cancer cell lines. Expression of the Notch
ligand Delta-like 1 is required for transformation of
human mammary epithelial cells [46], and was 5 fold
increased in the SRC1-/- mouse model. In this case
upregulation of Delta-like 1 expression may help to
compensate for loss of SRC1 in mammary tumorigen-
esis. Inhibition of Janus kinase 1 activation has been
observed in human breast cancer [47], and its expres-
sion was downregulated by -3.5 fold in SRC1-/- mam-
mary tumors. Members of the claudin family of tight
junction proteins are epigenetically silenced in human
breast cancer [48]; expression of claudin 10 was
decreased by -81.2 fold in SRC1-/- mammary tumors.
These results indicate that mammary tumors in the
SRC1-/-;neu mouse recapitulate a number of gene
expression changes in human breast cancer.
SRC-3 is another member of the SRC gene family,
which is specifically amplified in breast cancer [49]. The
SRC-3 null mutation inhibits mammary gland develop-
ment, partly due to decreased estrogen levels in these
mice [50]. Previous studies demonstrated that mice lack-
ing SRC-3 were resistant to chemical carcinogen and ras
oncoprotein induced mammary carcinogenesis [51],
similar to the results of our present SRC-1 study. Since
both SRC-1 and SRC-3 can interact with PPAR and
RXR, the similar molecular mechanism by which ligand
activated PPAR and RXR recruit SRC-1 and CBP from
the EGFR promoter may also partially explain the pro-
moting effect of SRC-3 overexpression in mammary
tumorigenesis. On the other hand, the role of SRC-1 as
a transcriptional coactivator of PPAR and RXR may also
contribute to the PPAR/RXR mediated suppression of
mammary tumorigenesis since SRC1-/- tumors were less
sensitive to the inhibitory effects of PPARg and RXR
ligands. This expectation is consistent with a previous
study showing that haploinsufficiency of AIB3
(NCOA6), a coactivator required for PPAR and RXR
transcriptional activity, accelerated mammary tumor
development in MMTV-polyoma middle T antigen
mouse model and the AIB3+/- tumors also were less
sensitive to the inhibitory effects of PPARg and RXR
ligands [52]. However, SRC-1 expression was not
required for the peroxisome proliferation response to
fibrates in the liver [53]. Expression of the PPARg coac-
tivator 1a (PGC1a)w a sd o w n r e g u l a t e di nS R C 1 - / -
tumors by -7.2 fold, which may contribute to the
decreased sensitivity of these tumors to PPAR ligands.
In summary, histone acetyltransferases SRC-1 and
CBP mediate resistance to nuclear receptor ligands and
increased proliferation in human breast cancer cells.
SRC-1 also plays a key role in initiation of mammary
tumorigenesis in vivo, which is associated with changes
in gene expression important to human breast cancer.
Some of the limitations of the study include downregu-
lation of PCG1a in SRC1-/-;neu mice which recruits
other histone acetyltransferases such as CBP to PPARs.
Additionally the effects of other mammary tumor pro-
moting oncogenes such as Wnt1 and ras may alter the
e f f e c t so fS R C 1d e l e t i o n .F u ture experiments will use
these model to further dissect molecular signaling path-
ways relevant to human breast cancer.
Conclusions
SRC-1 null mutation increased mammary tumor latency
and decreased metastasis in neu transgenic mice and
reduced the inhibitory effects of PPAR and RXR ligands.
SRC1-/- mammary tumors were less proliferative and
more differentiated with respect to gene expression than
SRC1+/+ cancers. PPAR and RXR selective ligands were
effective inhibitors of breast cancer cell proliferation in
vitro. PPAR and RXR ligands inhibited multiple overlap-
ping cell cycle regulatory proteins in human breast can-
cer cell lines. PPAR and RXR ligands inhibited
interaction of coactivator proteins with key growth regu-
l a t o r yg e n e ss u c ha sE G F R .C o a c t i v a t o r si n d u c e dr e s i s -
tance to inhibition of EGFR promoter activity by
nuclear receptor ligands. Coactivator overexpression
increased cell proliferation and induced resistance to
growth inhibition by PPAR and RXR ligands, which cor-
related with cell cycle regulatory gene expression. SRC-1
and CBP acetylated histones in the proximal EGFR pro-
moter, which correlated with increased gene expression
and resistance to the growth inhibitory effects of PPAR
and RXR ligands.
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